TrialBlood neoplasia2025

Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis.

Abdulraheem Yacoub et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.